James M McNally1, Robert W McCarley. 1. Laboratory of Neuroscience, VA Boston Healthcare System and Department of Psychiatry, Harvard Medical School, Brockton, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumin gamma-aminobutyric acid (GABA) neurons in the disease state. RECENT FINDINGS: Clinical electrophysiological studies of schizophrenia patients and pharmacological models of the disorder show an increase in spontaneous γ band activity (not stimulus-evoked) measures. These findings provide a crucial link between preclinical and clinical work examining the role of γ band activity in schizophrenia. MRI-based experiments measuring cortical GABA provides evidence supporting impaired GABAergic neurotransmission in schizophrenia patients, which is correlated with γ band activity level. Several studies suggest that stimulation of the cortical circuitry, directly or via subcortical structures, has the potential to modulate cortical γ activity, and improve cognitive function. SUMMARY: Abnormal γ band activity is observed in patients with schizophrenia and disease models in animals, and is suggested to underlie the psychosis and cognitive/perceptual deficits. Convergent evidence from both clinical and preclinical studies suggest the central factor in γ band abnormalities is impaired GABAergic neurotransmission, particularly in a subclass of neurons which express parvalbumin. Rescue of γ band abnormalities presents an intriguing option for therapeutic intervention.
PURPOSE OF REVIEW: We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumingamma-aminobutyric acid (GABA) neurons in the disease state. RECENT FINDINGS: Clinical electrophysiological studies of schizophreniapatients and pharmacological models of the disorder show an increase in spontaneous γ band activity (not stimulus-evoked) measures. These findings provide a crucial link between preclinical and clinical work examining the role of γ band activity in schizophrenia. MRI-based experiments measuring cortical GABA provides evidence supporting impaired GABAergic neurotransmission in schizophreniapatients, which is correlated with γ band activity level. Several studies suggest that stimulation of the cortical circuitry, directly or via subcortical structures, has the potential to modulate cortical γ activity, and improve cognitive function. SUMMARY: Abnormal γ band activity is observed in patients with schizophrenia and disease models in animals, and is suggested to underlie the psychosis and cognitive/perceptual deficits. Convergent evidence from both clinical and preclinical studies suggest the central factor in γ band abnormalities is impaired GABAergic neurotransmission, particularly in a subclass of neurons which express parvalbumin. Rescue of γ band abnormalities presents an intriguing option for therapeutic intervention.
Authors: Norbert Hájos; János Pálhalmi; Edward O Mann; Beáta Németh; Ole Paulsen; Tamas F Freund Journal: J Neurosci Date: 2004-10-13 Impact factor: 6.167
Authors: Faranak Farzan; Mera S Barr; Yinming Sun; Paul B Fitzgerald; Zafiris J Daskalakis Journal: Ann N Y Acad Sci Date: 2012-07-23 Impact factor: 5.691
Authors: Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter Journal: J Neurosci Date: 2010-03-10 Impact factor: 6.167
Authors: David A Lewis; Raymond Y Cho; Cameron S Carter; Kevin Eklund; Sarah Forster; Mary Ann Kelly; Debra Montrose Journal: Am J Psychiatry Date: 2008-10-15 Impact factor: 18.112
Authors: K G Phillips; M C Cotel; A P McCarthy; D M Edgar; M Tricklebank; M J O'Neill; M W Jones; K A Wafford Journal: Neuropharmacology Date: 2011-04-19 Impact factor: 5.250
Authors: Gregory A Light; Wen Zhang; Yash B Joshi; Savita Bhakta; Jo A Talledo; Neal R Swerdlow Journal: Neuropsychopharmacology Date: 2017-04-20 Impact factor: 7.853
Authors: Migyung Lee; Andrea Balla; Henry Sershen; Pejman Sehatpour; Peter Lakatos; Daniel C Javitt Journal: Neuropsychopharmacology Date: 2017-08-17 Impact factor: 7.853